Core Viewpoint - The announcement details the results of a share transfer by Shenzhen Koyi Pharmaceutical Holdings Co., Ltd., which is the controlling shareholder of Kexing Biopharmaceutical Co., Ltd. The transfer involves a reduction in the shareholding percentage of Koyi Pharmaceutical and its concerted actor, Deng Xueqin, from 63.89% to 60.38% after the transfer of 6,037,717 shares at a price of 36.70 yuan per share [2][4][9]. Group 1 - The share transfer price is set at 36.70 yuan per share, with a total of 6,037,717 shares being transferred [2]. - The controlling shareholder, Koyi Pharmaceutical, is involved in this share transfer [3]. - The transfer results in a passive dilution of shares, and there will be no change in the company's controlling shareholder or actual controller [4]. Group 2 - As of July 30, 2025, Koyi Pharmaceutical held more than 5% of the company's shares and is the controlling shareholder, which is controlled by Deng Xueqin [5]. - Koyi Pharmaceutical and Deng Xueqin are in a concerted action relationship [6]. - Following the share transfer, Koyi Pharmaceutical and Deng Xueqin's combined shareholding will decrease from 63.89% to 60.38% [8]. Group 3 - The total share capital of the company increased from 199,642,250 shares to 201,257,250 shares due to the completion of the first vesting period of the 2024 restricted stock incentive plan [8]. - The share transfer on August 5, 2025, accounted for 3.00% of the company's total share capital [9]. - The transfer process involved 95 institutional investors, with 14 valid bids received during the subscription period [12].

Core Viewpoint - The announcement details the results of a share transfer by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., which is the controlling shareholder of Kexing Pharmaceutical Co., Ltd. The transfer involves 6,037,717 shares at a price of 36.70 yuan per share, leading to a dilution of the controlling shareholder's stake from 63.89% to 60.38% [1][3]. Group 1: Transfer Details - The share transfer price is set at 36.70 yuan per share, with a total of 6,037,717 shares being transferred [1]. - The controlling shareholder, Keyi Pharmaceutical, is involved in this transfer, which is classified as a passive dilution and will not change the actual controller of the company [1][5]. - After the transfer, Keyi Pharmaceutical and its concerted actor, Deng Xueqin, will hold a total of 121,515,555 shares, reducing their ownership percentage from 63.89% to 60.38% [2][3]. Group 2: Shareholder Information - Keyi Pharmaceutical is the controlling shareholder and is controlled by Deng Xueqin, who is also the chairman of the company [2]. - The total share capital of the company increased from 199,642,250 shares to 201,257,250 shares due to this transfer [2]. - The ownership percentage of Keyi Pharmaceutical and its concerted actor will decrease from 63.89% to 60.38% following the transfer [3]. Group 3: Regulatory Compliance - The share transfer process was reviewed by China International Capital Corporation, which confirmed that it adhered to fair and just principles and complied with relevant securities market regulations [5]. - The transfer process followed the guidelines set forth by various laws and regulations, ensuring compliance with the requirements for share transfers in the market [5].

证券代码：688136 证券简称：科兴制药 公告编号：2025-057 科兴生物制药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%整数倍的提示性公告 深圳科益医药控股有限公司（以下简称"科益医药"或"转让方"）及其一致行动 人邓学勤保证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的价格为36.70元/股，转让的股票数量为6,037,717股。 公司控股股东参与本次询价转让。 本次权益变动为被动稀释、询价转让，本次转让不会导致公司控股股东、 实际控制人发生变化。 本次询价转让完成后，科益医药及其一致行动人邓学勤先生合计持有本 公司 121,515,555 股股份，占公司总股本的比例由权益变动前的由63.89%减少至 60.38%，累计权益变动比例触及 1%的整数倍。 一、 转让方情况 (一)转让方基本情况 本次询价转让的转让方科益医药持有公司股份比例超过 5%，为公司控股 股东，系公司实际控制人、董事长邓学 ...

股东向特定机构投资者询价转让股份的核查报告 中国国际金融股份有限公司 关于科兴生物制药股份有限公司 中国国际金融股份有限公司（以下简称"中金公司""组织券商"）受科兴生物 制药股份有限公司（以下简称"科兴制药""公司""上市公司"）股东深圳科益医 药控股有限公司（以下简称"深圳科益""出让方"）委托，组织实施本次科兴制药 股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 经核查，中金公司就本次询价转让的出让方、受让方是否符合《上海证券交易所 科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称"《询价转让 和配售指引》"）要求，本次询价转让的询价、转让过程与结果是否公平、公正，是 否符合《询价转让和配售指引》的规定作出如下报告说明。 一、本次询价转让概述 （一）本次询价转让出让方 截至2025年7月30日，出让方所持公司股份的数量、比例情况如下： | 出让方名称 | 截至2025年7月30日收盘持股数量（股） | 持股比例 | | --- | --- | --- | | 深圳科益 | 125,789,147 | 62.50% | （二）本次询价转让数量 本次拟询价转让股数上限为 6,0 ...

Group 1 - The core point of the article is that Sinovac Biotech has reached an agreement with Chongqing Zhifei Biological Products Co., Ltd. for the commercialization rights of a new drug, Anladiwei tablets, in Macau [1] - Anladiwei tablets are the world's first innovative drug targeting the PB2 protein of the RNA polymerase of the influenza A virus [1] - This development represents a significant breakthrough for domestic drugs in the antiviral field [1]

Group 1 - The A-share market is experiencing a significant increase in share buybacks, with 387 companies disclosing buyback progress since July, involving a total amount of 602.42 billion yuan [1][2] - Among the companies implementing buybacks, 246 have received special loans to support these actions, accounting for over 60% of the total [1][4] - Leading companies in buyback amounts include Kweichow Moutai, which has repurchased shares worth 5.301 billion yuan, and others like Muyuan Foods and Midea Group, each exceeding 1 billion yuan in buybacks [2][4] Group 2 - Kweichow Moutai's buyback plan, initially announced in September 2022, aims to reduce registered capital, with a total of 345.17 million shares repurchased, representing 0.2748% of its total share capital [2][3] - Muyuan Foods has repurchased 53.63 million shares for a total of 2.16 billion yuan, with a buyback price range between 36.16 yuan and 46.20 yuan per share [4][5] - Chip Original Co. completed its buyback plan within a week of announcing it, spending approximately 24.83 million yuan to repurchase 287,000 shares [3] Group 3 - The sectors most active in share buybacks include biopharmaceuticals, electronics, power equipment, and machinery, with each sector having over 30 companies participating and total buyback amounts exceeding 3 billion yuan [3] - Since the launch of the special loan program for buybacks, 653 companies have received support, with a total loan limit of 1,418.17 billion yuan, of which 894.21 billion yuan is allocated for share buybacks [4][5] - Companies like CAE Technology and Shandong Road and Bridge have also quickly completed their buyback plans after securing special loans [6]

Group 1: Pharmaceutical Regulations - Starting from August 1, all retail pharmacies in Foshan will implement a real-name registration system for the sale of 47 key controlled drugs, primarily for treating symptoms of Chikungunya fever [1] - The list of controlled drugs includes common medications such as Ibuprofen, Compound Cold Medicine, and Lianhua Qingwen capsules [1] Group 2: Clinical Trials and Drug Approvals - Kangning Jereh's innovative drug JSKN022, a PD-L1/αvβ6 dual-specific antibody drug conjugate, has received acceptance for clinical trial application from the National Medical Products Administration [3] - Yipin Hong's innovative drug APH03621 for endometriosis treatment has also received clinical trial registration acceptance from the National Medical Products Administration [5] - Lianhua Pharmaceutical's subsidiary has passed the consistency evaluation for the generic drug Lincomycin Hydrochloride Injection [4] Group 3: Financial Performance - China Resources Medical expects a profit decline of 20% to 25% for the first half of the year, with a significant drop of 55% to 60% when excluding one-time gains [6] - Zhenghai Bio reported a net profit of 46.49 million yuan for the first half of 2025, a decrease of 45.97% year-on-year, with revenue of 188 million yuan, down 5.14% [8] Group 4: Corporate Actions - Kexing Bio has spent 47.38 million yuan to repurchase 1.27 million shares, representing 0.63% of its total share capital [8] - WuXi AppTec has repurchased 6.51 million A-shares for a total of 497 million yuan [10] - Tian Tan Bio has decided to abandon the acquisition opportunity of Pailin Bio due to potential competition with its core business [9] Group 5: Industry Developments - Significant progress has been made in HIV vaccine research in China, with the completion of the first phase clinical trial for a replicating Tian Tan smallpox vaccine carrier HIV vaccine [11][13] - Sanofi announced the discontinuation of its PCSK9 inhibitor drug Alirocumab in China due to global supply issues and a strategic shift in its cardiovascular product line [12]

Core Viewpoint - The A-share market is experiencing a significant increase in share buybacks, with over 387 companies disclosing buyback progress since July, totaling 602.42 billion yuan in value [1][3]. Group 1: Buyback Activity - As of August 4, 2023, 387 A-share companies have reported buyback progress, with a total amount of 602.42 billion yuan involved [1]. - Among the companies that have implemented buybacks, 246 have received special loans for buybacks, accounting for over 60% [1][3]. - Guizhou Moutai leads in buyback amounts, having repurchased shares worth 5.301 billion yuan, representing 0.2748% of its total share capital [1]. Group 2: Industry Participation - The most active sectors in share buybacks include biopharmaceuticals, electronics, power equipment, and machinery, each with over 30 companies participating and a total buyback amount exceeding 30 billion yuan [3]. - Companies like Sany Heavy Industry and Midea Group have also reported significant buyback amounts, with Sany having repurchased shares worth 1.355 billion yuan [2]. Group 3: Loan Utilization - Since the launch of the buyback loan program, 653 companies have received support, with a total loan limit of 1,418.17 billion yuan, of which 894.21 billion yuan is allocated for share buybacks [3]. - Companies such as Muyuan Foods and BOE Technology have secured substantial buyback loan limits exceeding 1 billion yuan [3]. - The rapid implementation of buybacks is often facilitated by special loans, as seen with companies like Kailong High-Tech, which quickly completed its buyback after securing a loan [4].

（文章来源：证券日报） 证券日报网讯 8月4日晚间，科兴制药发布公告称，截至2025年7月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式已累计回购公司股份1，269，333股，占公司目前总股本的比例为0.63%。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-056 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/19 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 3 3 | 17 | 日~2026 | 年 | 月 | 16 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | | | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | 回购用途 | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 1,269,333股 | | | | | | | | 累计已回购股数占总股本比例 | 0.63% | | | | | ...